TIDMAZN

RNS Number : 6730N

AstraZeneca PLC

10 August 2017

10 August 2017 13:30 BST

Publication of Prospectus

Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:

Base Prospectus for the AstraZeneca PLC U.S. $5,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

The last drawdown under the EMTN programme was in 2016.

To view the full document, please paste the following URL into the address bar of your browser.

http://www.rns-pdf.londonstockexchange.com/rns/6730N_-2017-8-10.pdf

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

http://www.morningstar.co.uk/uk/NSM

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 
 Media Relations 
 Esra Erkal-Paler       UK/Global                                           +44 203 749 5638 
 Rob Skelding           UK/Global                                           +44 203 749 5821 
 Karen Birmingham       UK/Global                                           +44 203 749 5634 
 Matt Kent              UK/Global                                           +44 203 749 5906 
 Jacob Lund             Sweden                                              +46 8 553 260 20 
 Michele Meixell        US                                                   +1 302 885 2677 
 
 Investor Relations 
 Thomas Kudsk Larsen                                                        +44 203 749 5712 
 Craig Marks            Finance, Fixed Income, M&A                          +44 7881 615 764 
 Henry Wheeler          Oncology                                            +44 203 749 5797 
 Mitchell Chan          Oncology                                             +1 240 477 3771 
 Christer Gruvris       Diabetes; Autoimmunity, Neuroscience & Infection    +44 203 749 5711 
 Nick Stone             Respiratory; Brilinta                               +44 203 749 5716 
 US toll free                                                                +1 866 381 7277

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS

The company news service from the London Stock Exchange

END

PDIOKKDNDBKDOFD

(END) Dow Jones Newswires

August 10, 2017 08:30 ET (12:30 GMT)

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Astrazeneca Charts.